Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform, which is for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline, which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor, drug targets and the other used to generate antibodies.